Integra LifeSciences (NASDAQ:IART) Given New $18.00 Price Target at Wells Fargo & Company

Posted by George Bondi on Jul 31st, 2026

Integra LifeSciences (NASDAQ:IART – Free Report) had its price objective increased by Wells Fargo & Company from $15.00 to $18.00 in a report published on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the life sciences company’s stock.

A number of other research firms have also recently weighed in on IART. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Thursday, June 18th. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price for the company. Truist Financial raised their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Citigroup reaffirmed a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Integra LifeSciences currently has an average rating of “Reduce” and an average price target of $18.86.

Check Out Our Latest Analysis on IART

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $17.10 on Thursday. Integra LifeSciences has a one year low of $8.70 and a one year high of $20.49. The stock’s fifty day moving average is $17.67 and its 200 day moving average is $13.45. The stock has a market cap of $1.33 billion, a P/E ratio of -189.95, a P/E/G ratio of 1.14 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.31% and a negative net margin of 0.44%.The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Integra LifeSciences in the 1st quarter worth approximately $277,000. Goldman Sachs Group Inc. grew its holdings in Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after buying an additional 35,790 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Integra LifeSciences by 23.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after buying an additional 45,693 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Integra LifeSciences during the second quarter valued at approximately $491,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

More Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

Positive Sentiment: Q2 earnings beat expectations: Integra reported adjusted earnings of $0.56 per share, up from $0.45 a year earlier and above the $0.48 consensus estimate. Revenue of $418.8 million was also slightly ahead of expectations. Integra LifeSciences Reports Second Quarter 2026 Financial Results
Positive Sentiment: Analyst price target raised: Wells Fargo increased its target from $15 to $18 while maintaining an “equal weight” rating. The higher target signals improved valuation expectations, although the unchanged rating limits the bullish impact. Wells Fargo raises Integra price target
Positive Sentiment: Technical momentum remains favorable: IART was identified as a potential breakout stock after trading near its 52-week high and passing technical screens, which may attract momentum-oriented investors. Stocks showing breakout potential
Neutral Sentiment: Full-year outlook was maintained near consensus: Integra expects 2026 EPS of $2.40-$2.50 and revenue of approximately $1.7 billion, broadly matching analyst expectations.
Neutral Sentiment: New analyst coverage: UBS began coverage of Integra, adding institutional attention; the available report does not specify its rating or price target. UBS begins coverage on Integra LifeSciences
Negative Sentiment: Q3 guidance offers limited upside: EPS guidance of $0.53-$0.61 and revenue guidance of $410 million-$425 million bracket consensus estimates, suggesting expectations are largely embedded rather than being raised. Integra also reported a negative net margin, underscoring ongoing profitability concerns.

Integra LifeSciences Company Profile

(Get Free Report)

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.